NDATOPICALLOTION
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
6/8 — Strong
DUOBRII (halobetasol propionate and tazarotene) by Bausch + Lomb. Approved for retinoid [epc]. First approved in 2019.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUOBRII is a fixed-dose combination topical lotion containing halobetasol propionate (potent corticosteroid) and tazarotene (retinoid) approved in 2019 for plaque psoriasis. It works by combining anti-inflammatory and keratinocyte-differentiating mechanisms to reduce psoriatic plaques and inflammation.
$0.927MPart D
Peak10.1 years to LOEPeak-lifecycle product with modest Medicare utilization signals stable commercial investment but limited near-term growth trajectory for brand expansion roles.
Mechanism of Action
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Duobrii Treatment of Acne Keloidalis Nuchae (AKN)
Started Oct 2022
15 enrolled
Acne Keloidalis NuchaeAKN
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Career Relevance
DUOBRII currently shows zero linked job openings, reflecting its mature market status as a niche fixed-dose combination within Bausch + Lomb's dermatology portfolio. Career opportunities are likely concentrated in ongoing brand management, medical affairs, and sales support rather than expansion or new development roles.
Worked on DUOBRII at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.